2025-08-25
Changning District Medical Insurance Bureau Visits Baheal Pharma: Government and Enterprise Join Forces to Explore New Pathways for Medical Insurance Support of Innovative Drugs and Devices
On August 21, 2025, Zhu Lingfang, Deputy Director of the Shanghai Changning District Medical Insurance Bureau, led a delegation of relevant department heads to visit Shanghai Baheal Pharmaceutical Co., Ltd. (hereinafter referred to as “Baheal Pharma”) for a research and discussion session. Li Zhenghua, Vice President of Baheal Pharma, along with the management team, warmly received the guests. The two sides engaged in extensive and in-depth exchanges on topics such as the implementation of medical insurance policies, access to innovative products, and industrial development. This visit was not only a routine work inspection but also a practical effort aimed at promoting government-enterprise communication and providing targeted services to key enterprises in the district.


The meeting focused on the current most concerning medical insurance policy issues for enterprises, and both sides had frank communication. The enterprise elaborated on the clinical value and market positioning of its main products, expressing its demand for high-quality development. The delegation from the district medical insurance bureau listened carefully to the introduction of the situation and stated that they will actively play a bridging role to provide reasonable suggestions from enterprises to municipal departments.
Building a Platform for Innovative Drugs and Devices: District Medical Insurance Bureau Proactively Extends an “Olive Branch”
During the exchange, Deputy Director Zhu Lingfang specifically introduced the key functions of the Treatment Security Department of the district medical insurance bureau—actively supporting the implementation of the municipal-level “28 Articles policy aimed at promoting innovative drugs and devices. She emphasized that to support the high-quality development of Shanghai’s biomedical industry, the district medical insurance bureau is focused on building a platform for the use and promotion of “new and superior drugs and devices” for innovative enterprises like Baheal in the district. This aims to bridge the “last mile” of policy implementation, helping more high-quality products that are clinically needed and technologically innovative to be applied more quickly and effectively in clinical settings for the benefit of patients.

Deputy Director Zhu’s introduction broadened the perspective of the discussion. Ms. Zheng Ming, Strategic Client Director of Baheal Medical Group, subsequently elaborated on the group’s strategic layout and cutting-edge achievements in innovative medical devices and high-value pharmaceuticals. She stated that the group is continuously increasing its R&D investment and looks forward to these innovations being more efficiently delivered to medical institutions and patients in Shanghai and across the country through channels such as the “new and superior drugs and devices” platform.

In response, Deputy Director Zhu Lingfang noted that in addition to supporting innovative drugs and devices, the Changning District Medical Insurance Bureau also undertakes diverse public service functions such as policy promotion, fund supervision, designated institution management, long-term care insurance pilots, and assistance. She emphasized that the core of medical insurance work remains “ensuring basic needs, securing line, and promoting fairness,” hoping that enterprises could gain a more comprehensive understanding of medical insurance work to receive more targeted support.
The meeting yielded fruitful results and was conducted in a warm atmosphere. It not only deepened mutual understanding between the medical insurance department and pharmaceutical enterprises but also outlined a clear path for government-enterprise collaboration and joint development. Both sides agreed to establish a smoother regular communication mechanism to jointly explore how to more effectively balance policy implementation, industrial innovation, and patient benefits amid the broader context of healthcare reform. Together, they aim to contribute the “Changning model” and strength to the construction of “Healthy Shanghai” and “Healthy China.”
Related News